Skip to content

This website is a third-party information service. It does not provide medical care or operate a treatment facility.

Phase 3 Cancer Trials

New Haven, Connecticut

Phase 3 cancer trials in New Haven, CT

49 Phase 3 cancer studies are recruiting participants at sites in New Haven as of November 18, 2026, according to ClinicalTrials.gov. Phase 3 Cancer Trials can help you understand your options and connect with a study team.

Call (888) 306-7888
  • No cost to ask
  • Taking part is voluntary
  • Studies are independently reviewed

New Haven at a glance

Breast cancer studies recruiting in New Haven

Basic details from each study's public record (the 30 most recently updated of 49). Select a study to read the full record on ClinicalTrials.gov, including how to contact its team.

  1. Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Yale Cancer Center ( Site 0053)
    Registry record
    NCT06393374 · updated
  2. Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Yale University
    Registry record
    NCT06058377 · updated
  3. Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Relay Therapeutics, Inc.
    Study site
    Yale-New Haven Hospital-Yale Cancer Center
    Registry record
    NCT06982521 · updated
  4. Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25

    • Phase 3
    • Ages 18 to 60
    • Female participants
    Sponsor
    NRG Oncology
    Study site
    Yale University
    Registry record
    NCT05879926 · updated
  5. The CDK4/6 Inhibitor Dosing Knowledge (CDK) Study

    • Phase 3
    • Ages 60 and older
    • All sexes
    Sponsor
    American Society of Clinical Oncology
    Study sites
    Smilow Cancer Hospital - Yale New Haven Health · Yale University/Yale Cancer Center/Yale School of Medicine
    Registry record
    NCT06377852 · updated
  6. The Cancer of the Pancreas Screening-5 CAPS5)Study

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Johns Hopkins University
    Study site
    Yale University
    Registry record
    NCT02000089 · updated
  7. A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Pfizer
    Study sites
    Smilow Cancer Hospital - Yale New Haven Health · Yale-New Haven Hospital
    Registry record
    NCT07062965 · updated
  8. Adding Surgery and Radiation to the Usual Treatment for HER2-Positive Breast Cancer That Had Already Spread at Diagnosis

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    SWOG Cancer Research Network
    Study sites
    Smilow Cancer Center/Yale-New Haven Hospital · Yale University
    Registry record
    NCT07578116 · updated

Source: ClinicalTrials.gov. Data processed . See every breast cancer study recruiting in New Haven, CT on ClinicalTrials.gov.

Lung cancer studies recruiting in New Haven

  1. A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Yale University School of Medicine ( Site 0201)
    Registry record
    NCT06623422 · updated
  2. A Clinical Trial of Adjuvant Intismeran (V940) With or Without Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) in High-Risk Stage I Non-Small Cell Lung Cancer (V940-014)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Smilow Cancer Center at Yale-New Haven ( Site 3253)
    Registry record
    NCT07513376 · updated
  3. Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Yale University
    Registry record
    NCT04267848 · updated
  4. Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Yale University
    Registry record
    NCT04181060 · updated
  5. A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Eli Lilly and Company
    Study site
    Yale University School of Medicine
    Registry record
    NCT06119581 · updated
  6. A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Zai Lab (Shanghai) Co., Ltd.
    Study site
    Yale Cancer Center/Clinical Trials Office
    Registry record
    NCT07218146 · updated

Source: ClinicalTrials.gov. Data processed . See every lung cancer study recruiting in New Haven, CT on ClinicalTrials.gov.

Prostate cancer studies recruiting in New Haven

  1. Study of Opevesostat (MK-5684) Versus Alternative NHA in mCRPC (MK-5684-003)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Yale-New Haven Hospital-Yale Cancer Center ( Site 0064)
    Registry record
    NCT06136624 · updated
  2. A Clinical Study of Ifinatamab Deruxtecan (I-DXd) in People With Metastatic Prostate Cancer (MK-2400-001)

    • Phase 3
    • Ages 18 and older
    • Male participants
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Yale-New Haven Hospital-Yale Cancer Center ( Site 0050)
    Registry record
    NCT06925737 · updated
  3. A Study of Opevesostat (MK-5684) Versus Alternative Next-generation Hormonal Agent (NHA) in Metastatic Castration-resistant Prostate Cancer (mCRPC) Post One NHA (MK-5684-004)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Merck Sharp & Dohme LLC
    Study site
    Yale-New Haven Hospital-Yale Cancer Center ( Site 0064)
    Registry record
    NCT06136650 · updated

Source: ClinicalTrials.gov. Data processed . See every prostate cancer study recruiting in New Haven, CT on ClinicalTrials.gov.

Melanoma studies recruiting in New Haven

  1. A Study With Combinations of Anti-LAG-3 and Anti-PD-1 Antibodies in Adult Participants With Advanced or Metastatic Melanoma (Harmony Head-to-Head)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Regeneron Pharmaceuticals
    Study site
    Yale Cancer Center
    Registry record
    NCT06246916 · updated
  2. SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous Melanoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Immatics US, Inc.
    Study site
    Yale Cancer Center
    Registry record
    NCT06743126 · updated

Source: ClinicalTrials.gov. Data processed . See every melanoma study recruiting in New Haven, CT on ClinicalTrials.gov.

Lymphoma studies recruiting in New Haven

  1. SIGMA (Safusidenib in IDH1 Mutant Glioma Maintenance)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Nuvation Bio Inc.
    Study site
    Yale University
    Registry record
    NCT05303519 · updated
  2. A Study to Compare Standard Therapy to Treat Hodgkin Lymphoma to the Use of Two Drugs, Brentuximab Vedotin and Nivolumab

    • Phase 3
    • Ages 5 to 60
    • All sexes
    Sponsor
    National Cancer Institute (NCI)
    Study site
    Yale University
    Registry record
    NCT05675410 · updated
  3. A Study to Evaluate Glofitamab as a Single Agent vs. Investigator's Choice in Participants With Relapsed/Refractory Mantle Cell Lymphoma

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Hoffmann-La Roche
    Study site
    Yale Cancer Center
    Registry record
    NCT06084936 · updated
  4. Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia

    • Phase 3
    • Ages 18 to 39
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study site
    Yale University
    Registry record
    NCT03150693 · updated
  5. Testing Continuous Versus Intermittent Treatment With the Study Drug Zanubrutinib for Older Patients With Previously Untreated Mantle Cell Lymphoma

    • Phase 3
    • Ages 60 and older
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study site
    Yale University
    Registry record
    NCT05976763 · updated
  6. Testing Addition of an Anti-cancer Drug, Vorasidenib to Temozolomide, After Radiation for Advanced Brain Cancer

    • Phase 3
    • Ages 12 and older
    • All sexes
    Sponsor
    Alliance for Clinical Trials in Oncology
    Study site
    Yale University
    Registry record
    NCT07215910 · updated
  7. A Study to Investigate the Efficacy and Safety of Sonrotoclax Plus Zanubrutinib Compared With Placebo Plus Zanubrutinib in Adults With Relapsed/Refractory Mantle Cell Lymphoma (CELESTIAL-RRMCL)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    BeOne Medicines
    Study site
    Yale University Yale Cancer Center
    Registry record
    NCT06742996 · updated
  8. IGNITE: Study of Tirabrutinib vs Rituximab and Temozolomide for Relapsed/Refractory Primary Central Nervous System Lymphoma (PCNSL)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Ono Pharmaceutical Co., Ltd.
    Study site
    Yale Cancer Center
    Registry record
    NCT07104032 · updated
  9. A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    BeOne Medicines
    Study site
    Yale University Yale Cancer Center
    Registry record
    NCT06943872 · updated
  10. A Study of Surovatamig (AZD0486) Plus Rituximab in Previously Untreated Follicular Lymphoma Patients

    • Phase 3
    • Ages 18 to 130
    • All sexes
    Sponsor
    AstraZeneca
    Registry record
    NCT06549595 · updated

Source: ClinicalTrials.gov. Data processed . See every lymphoma study recruiting in New Haven, CT on ClinicalTrials.gov.

Pancreatic cancer studies recruiting in New Haven

  1. Study of Zoldonrasib + Chemo of Investigator's Choice vs Placebo + Chemo of Investigator's Choice as First-line Treatment in Metastatic KRAS G12D-mutated Pancreatic Adenocarcinoma ( RASolute 305 )

    • Phase 3
    • Ages 18 and older
    • All sexes
    Sponsor
    Revolution Medicines, Inc.
    Study site
    Yale University
    Registry record
    NCT07621718 · updated

Source: ClinicalTrials.gov. Data processed . See every pancreatic cancer study recruiting in New Haven, CT on ClinicalTrials.gov.

Ask about studies near New Haven

Tell us what you are looking for and a coordinator will contact you to talk through your options. Asking does not commit you to anything.

How should we reach you?
Add a message or the best time to reach you (optional)

Please do not include detailed medical information.

Before you contact a study

About these listings

These listings come from ClinicalTrials.gov, the study registry run by the U.S. National Library of Medicine. The data were processed on November 18, 2026. We show part of each public record (its title, phase, sponsor, basic eligibility and sites in this area) exactly as registered, and we group studies by place. Nothing in a record is reworded. This site lists only studies that are in Phase 3, including combined Phase 2/3, as each study is coded in the registry.

Phase 3 Cancer Trials does not run these studies and is not affiliated with their sponsors. A listing is not a recommendation, and only a study's own team can tell you whether you may be eligible. Follow the link on any study to read its full record and contact that team directly, or ask us and a coordinator will help you understand your options. How we source and check what we publish.

Sources and further reading

Ask about a study

A coordinator will contact you. Asking does not commit you to anything.

Call (888) 306-7888

or send a short form

How should we reach you?

Call